Kanglu Biotechnology

Wuhan Kanglu Biotechnology Joint-stock Co., Ltd. is located in Wuhan Optics Valley BioCity, the National Biological Industry Base. With precision medical diagnostic products for major diseases such as tumors and cardiovascular and cerebrovascular diseases as its strategic direction, the company is a high-tech enterprise integrating R&D, production, sales and testing services.
Since its establishment, the company has taken it as its mission to provide more efficient diagnostic products, adhered to independent research and development, and established a multidisciplinary R&D team covering clinical medicine, molecular biology, microfluidics, mechanical automation and other fields. The company owns 25 invention patents, and its FastProbe? rapid fluorescence in situ hybridization probe preparation technology with completely independent intellectual property rights is at a leading level. The new-generation probes prepared based on the patented technology require only 2 hours of hybridization incubation, shortening fluorescence in situ hybridization testing time from 3 days to several hours, and featuring higher sensitivity, specificity and signal-to-noise ratio.
The company's independently developed and internationally pioneering microfluidic chip fully automated cell fluorescence in situ hybridization platform, automatic fluorescence scanning system and computer artificial intelligence result interpretation system have realized rapid, automated, high-throughput and intelligent FISH testing of ***, peripheral blood and exfoliated cells, and this disruptive technology has greatly promoted the clinical application of fluorescence in situ hybridization technology. Based on technological and product advantages, the company has built a complete domestic and international marketing system. Its products have entered more than 20 countries and regions, winning a good market reputation and widespread customer recognition, and making it an internationally renowned rapid fluorescence in situ hybridization probe*.
The company will always adhere to the purpose of "Fast, Precise, Beyond" and tirelessly forge ahead to contribute to the development of precision medicine worldwide.
The company currently has three major product lines: FastProbe? rapid FISH probes, fully automated FISH equipment and pharmacogenomics PCR detection reagents.
FISH probes are used to detect chromosomal or gene abnormalities in cells or tissues, mainly for early tumor screening, auxiliary diagnosis, efficacy monitoring, individualized treatment and prognosis judgment. The company's completely independent intellectual property FastProbe? rapid fluorescence in situ hybridization probe preparation technology is at a leading level, shortening fluorescence in situ hybridization time from the traditional one day and one night to several hours, greatly improving testing efficiency and shortening patient waiting time. Solid tumor FISH probes can achieve rapid hybridization in 2 hours, with flexible hybridization time, fewer non-specific signals, clear and bright signal spots, and more convenient clinical interpretation, and are commonly used in clinical departments such as breast surgery, thoracic surgery, urology and oncology; blood tumor FISH probes have shortened testing time to within 2 hours, greatly improving testing efficiency and sustaining life for patients with acute onset and rapidly progressing blood diseases.
The company currently owns the nation's first fully automated slide processing system, realizing for the first time the full automation and standardized process of domestic-brand FISH pretreatment, and it has been put into market use; in 2020, the internationally pioneering microfluidic chip fully automated cell fluorescence in situ hybridization system, automatic fluorescence scanning system and computer artificial intelligence result interpretation system will also be launched.
The company's pharmacogenomics testing projects mainly use fluorescence quantitative PCR technology, which can provide medication guidance, risk prediction or health management for different types of diseases; it currently covers about more than one hundred detection reagents, and the products have the characteristics of excellent performance, wide applicability to departments, comprehensive testing items and convenient project implementation.
At present, the company has become the precision medicine in vitro diagnostic reagent brand with the most and most complete products in the domestic rapid FISH probe and pharmacogenomics PCR product fields!